CASP1 and colitis: Several potential therapeutic targets have emerged, including caspase-1 inhibitors, the preclinical studies have shown that inhibiting caspase-1 can reduce the severity of colitis in animal models, suggesting that pharmacological modulation of this enzyme may provide therapeutic benefits (Cao et al., 2024).